公开(公告)号：US20240287107A1

公开(公告)日：2024-08-29

申请号：US18541172

申请日：2024-05-01

Applicant: ATAI Therapeutics, Inc.

Inventor： Tanweer A. KHAN ,  Robert B. PERNI ,  Alan C. GIBBS

IPC: C07F9/572 ,  A61K31/675 ,  C07B59/00 ,  C07F9/6571

CPC classification number: C07F9/5728 ,  A61K31/675 ,  C07B59/004 ,  C07F9/657163 ,  C07B2200/05

Abstract: Provided herein are compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B), pharmaceutically acceptable salts thereof, and compositions thereof, wherein R1, R2, R3, R7, R8, R9, R10, R11, R12, R13, R14, A, B, E, W, X, and n are defined herein. The disclosed compounds are useful for treating various diseases, including depression and associated conditions.

公开(公告)号：US20240400511A1

公开(公告)日：2024-12-05

申请号：US18657306

申请日：2024-05-07

Applicant: ATAI Therapeutics, Inc.

Inventor： Robert B. PERNI ,  Glenn SHORT ,  Tanweer A. KHAN

IPC: C07D209/16

Abstract: Provided herein are compounds of Formula (I), (II), or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (II), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240376116A1

公开(公告)日：2024-11-14

申请号：US18646264

申请日：2024-04-25

Applicant: Atai Therapeutics, Inc.

Inventor： Tanweer A. KHAN ,  Glenn SHORT ,  Robert B. PERNI ,  Alan C. GIBBS ,  Jeffrey O'MEARA ,  Harpreet KAUR ,  Ahmed Magdy ALI

IPC: C07D487/22 ,  C07D491/22 ,  C07D495/22

Abstract: Provided herein are compounds of Formula (I), (II), (III), or pharmaceutically acceptable salt, prodrug, or steroisomer thereof, and compositions thereof, wherein R1, R1′, R2, R2′, R3, R6, R7, X1, X2, X3, X4, and Z are defined herein. The disclosed compounds are useful for treating various conditions, including alcoholism, substance abuse disorder, and opioid use disorder.

公开(公告)号：US12128027B2

公开(公告)日：2024-10-29

申请号：US18120033

申请日：2023-03-10

Applicant: ATAI Therapeutics, Inc.

Inventor： Srinivas G. Rao ,  Glen Short ,  Majed Fawaz ,  Prerak Patel ,  Santnu Patel

IPC: A61K31/4045 ,  A61K9/00 ,  A61K9/70 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61K47/42

CPC classification number: A61K31/4045 ,  A61K9/006 ,  A61K9/7007 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61K47/42

Abstract: Pharmaceutical compositions including an amorphous N—N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier are described. These compositions are suitable for buccal or sublingual administration to a patient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.

公开(公告)号：US12012381B2

公开(公告)日：2024-06-18

申请号：US18147499

申请日：2022-12-28

Applicant: ATAI Therapeutics, Inc.

Inventor： Robert B. Perni ,  Glenn Short ,  Tanweer A. Khan

IPC: C07D209/16

CPC classification number: C07D209/16 ,  C07B2200/05

Abstract: Provided herein are compounds of Formula (I), (II), or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (II), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240366531A1

公开(公告)日：2024-11-07

申请号：US18652721

申请日：2024-05-01

Applicant: Atai Therapeutics Inc.

Inventor： Carrie Bowen ,  Glenn F. Short ,  Thomas Cameron Robertson

IPC: A61K31/137 ,  A61P25/20 ,  A61P25/24

Abstract: Provided herein are compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (I-A), Formula (I-B) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), Formula (I-A), Formula (I-B) or pharmaceutically acceptable salt thereof. The current invention reports compounds to reduce REM sleep and/or non-REM sleep in a subject which can be effective in treating diseases or disorder where sleep is dysregulated. The methods of the disclosure include methods of treating sleep dysfunction, sleep disorder, stress related disorders, neuropsychiatric diseases, neurological conditions and/or neurodevelopmental disorders, using the compound of Formula (I), Formula (I-A), and/or Formula (I-B).

公开(公告)号：US20240325407A1

公开(公告)日：2024-10-03

申请号：US18666388

申请日：2024-05-16

Applicant: ATAI Therapeutics, Inc.

Inventor： Holger WEIS ,  Emeline MAILLET

IPC: A61K31/55 ,  A61K31/135 ,  A61K31/137 ,  A61K31/4025 ,  A61K31/439 ,  A61K31/4468 ,  A61K31/4535 ,  A61K31/485 ,  A61K36/24

CPC classification number: A61K31/55 ,  A61K31/135 ,  A61K31/137 ,  A61K31/4025 ,  A61K31/439 ,  A61K31/4468 ,  A61K31/4535 ,  A61K31/485 ,  A61K36/24

Abstract: Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.

公开(公告)号：US12065405B2

公开(公告)日：2024-08-20

申请号：US18299347

申请日：2023-04-12

Applicant: ATAI Therapeutics, Inc.

Inventor： Robert B. Perni ,  Glenn Short ,  Srinivas G. Rao ,  Tanweer A. Khan

IPC: C07D209/16 ,  C07D209/08 ,  C07D209/12 ,  C07D209/14 ,  C07D401/06 ,  C07D403/06 ,  C07F9/572

CPC classification number: C07D209/16 ,  C07D209/08 ,  C07D209/12 ,  C07D209/14 ,  C07D401/06 ,  C07D403/06 ,  C07F9/5728

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

公开(公告)号：US12016866B2

公开(公告)日：2024-06-25

申请号：US17580077

申请日：2022-01-20

Applicant: ATAI Therapeutics, Inc.

Inventor： Holger Weis ,  Emeline Maillet

IPC: A61K31/55 ,  A61K31/135 ,  A61K31/137 ,  A61K31/4025 ,  A61K31/439 ,  A61K31/4468 ,  A61K31/4535 ,  A61K31/485 ,  A61K36/24

CPC classification number: A61K31/55 ,  A61K31/135 ,  A61K31/137 ,  A61K31/4025 ,  A61K31/439 ,  A61K31/4468 ,  A61K31/4535 ,  A61K31/485 ,  A61K36/24 ,  A61K31/55 ,  A61K2300/00 ,  A61K31/485 ,  A61K2300/00 ,  A61K31/4468 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00 ,  A61K31/4535 ,  A61K2300/00 ,  A61K31/439 ,  A61K2300/00 ,  A61K31/4025 ,  A61K2300/00 ,  A61K31/135 ,  A61K2300/00 ,  A61K36/24 ,  A61K2300/00

Abstract: Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.

公开(公告)号：US20240199544A1

公开(公告)日：2024-06-20

申请号：US18526500

申请日：2023-12-01

Applicant: Atai Therapeutics, Inc.

Inventor： Majed Fawaz ,  Setu Kasera

IPC: C07D209/16 ,  A61K31/4045

CPC classification number: C07D209/16 ,  A61K31/4045

Abstract: The present disclosure provides crystalline forms of N,N-dimethyltryptamine,




Also provided herein are methods of using crystalline forms of N,N-DMT and compositions comprising the same, e.g., in the treatment of mental health diseases and/or disorders.